PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.16
D/E ratio 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 0.11. Seth Klarman would look for hidden assets or restructuring potential.
9.07
Dangerously high net debt exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.09. Michael Burry would check for debt covenant compliance and refinancing risks.
5.63
Coverage of 5.63 versus zero Drug Manufacturers - Specialty & Generic median interest expense. Walter Schloss would verify if our leverage provides advantages.
2.46
Current ratio near Drug Manufacturers - Specialty & Generic median of 2.46. David Dodd would examine if industry-standard liquidity is appropriate given business model.
74.99%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.74%. Michael Burry would check for aggressive accounting and hidden risks.